<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>With the global epidemic of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:mp ids='MP_0002055'>diabetes</z:mp> has become the leading cause of <z:hpo ids='HP_0003774'>end stage renal failure</z:hpo> (ESRF) in most Western countries </plain></SENT>
<SENT sid="1" pm="."><plain>Approximately 20-30% of <z:hpo ids='HP_0000001'>all</z:hpo> diabetic subjects will develop evidence of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, which represents a continuum from <z:mp ids='MP_0002959'>microalbuminuria</z:mp>, to overt <z:hpo ids='HP_0000112'>nephropathy</z:hpo> or macroalbuminuria, and finally ESRF </plain></SENT>
<SENT sid="2" pm="."><plain>While there have been significant breakthroughs in the last decade with regards to the prevention and treatment of <z:e sem="disease" ids="C0011881" disease_type="Disease or Syndrome" abbrv="">diabetic kidney disease</z:e>, in particular blockade of the renin angiotensin system, there is a vital need to identify and target novel pathophysiologic pathways such as advanced glycation which appear to be centrally involved in <z:e sem="disease" ids="C0011881" disease_type="Disease or Syndrome" abbrv="">diabetic renal disease</z:e> in order to reduce the rising burden of this disease </plain></SENT>
</text></document>